MedPath

Development and Testing a Counseling strategy for drug and alcohol misuse in prisons.

Not Applicable
Conditions
Health Condition 1: F10-F19- Mental and behavioral disorders due to psychoactive substance use
Registration Number
CTRI/2022/01/039182
Lead Sponsor
Indian Council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

ASSIST score in the â??moderate riskâ??. If the participant scores within the moderate-risk range for two or more of the target drugs, the intervention will be focused on the highest-scoring substance or the substance that is of most concern to the participant. Alcohol, in any case, receive the intervention. Inmates who will remain in the prison for at least 6 months following intervention; for under-trial prisoners, it will be decided on the basis of the next date of the court hearing.

Exclusion Criteria

Only tobacco use

Unable to provide informed consent for cognitive impairment.

Not willing to participate in the intervention and for follow-up assessments

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To develop the â??enhancedâ?? component of SBIRT <br/ ><br>2. Feasibility and acceptability of brief intervention for substance use disorders in prison population <br/ ><br>3. Reduction in the ASSIST score by more or equal to 7 points in the intervention arm compared to the control arm.Timepoint: Third and Sixth months.
Secondary Outcome Measures
NameTimeMethod
1. To identify the facilitators and barriers of the uptake of the intervention and to <br/ ><br>modify the intervention accordingly. <br/ ><br>2. Reduction in the frequency of illicit drug use in the intervention arm compared to <br/ ><br>the control <br/ ><br>3. Reduction in frequency of drinking days and heavy drinking days in the intervention arm compared to the control. <br/ ><br>4. Reduction of re incarceration <br/ ><br>5. Reduction of high-risk behavior. <br/ ><br>6. Reduction of overdose risk.Timepoint: 12 months
© Copyright 2025. All Rights Reserved by MedPath